Synthetic Genomics Acquires IP from Febit | GenomeWeb

NEW YORK (GenomeWeb News) – Synthetic Genomics today announced its acquisition of the worldwide rights to three families of patents and patent applications related to synthetic genomic technologies from Germany's Febit Holding.

Included in the deal are related know-how, equipment, and technical support for implementation, La Jolla, Calif.-based Synthetic Genomics said. Financial terms of the transaction were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.